1. Home
  2. NVTS vs AUPH Comparison

NVTS vs AUPH Comparison

Compare NVTS & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Navitas Semiconductor Corporation

NVTS

Navitas Semiconductor Corporation

HOLD

Current Price

$7.36

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.93

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVTS
AUPH
Founded
2014
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
NVTS
AUPH
Price
$7.36
$15.93
Analyst Decision
Buy
Buy
Analyst Count
6
4
Target Price
$5.92
$17.25
AVG Volume (30 Days)
17.5M
1.5M
Earning Date
11-03-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.55
Revenue
$56,598,000.00
$265,808,000.00
Revenue This Year
N/A
$21.22
Revenue Next Year
N/A
$15.40
P/E Ratio
N/A
$28.70
Revenue Growth
N/A
20.62
52 Week Low
$1.52
$6.55
52 Week High
$17.79
$16.48

Technical Indicators

Market Signals
Indicator
NVTS
AUPH
Relative Strength Index (RSI) 36.41 60.04
Support Level $8.01 $15.57
Resistance Level $10.24 $16.07
Average True Range (ATR) 0.67 0.48
MACD -0.10 -0.09
Stochastic Oscillator 0.00 75.93

Price Performance

Historical Comparison
NVTS
AUPH

About NVTS Navitas Semiconductor Corporation

Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components for use in mobile device and other markets. Geographically, the company operates in China, Europe, United States, Rest of Asia and Others. The majority of revenue is generated from China.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: